Figure 2 Components of each transplantation platform

Slides:

Advertisements

Similar presentations

First clinical results with αβ+ T-cell depleted haploidentical stem cells in children Children’s University Hospital, Tübingen, Germany P Lang, T Feuchtinger,

Advertisements

Alexander H. Schmidt, Thilo Mengling, Camila J

Supplemental table 1 Patients' characteristics Variables Number

Figure 1 Concept of the therapeutic index

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Morphological analyses of peripheral blood and bone marrow cells isolated from leukemic mice. Morphological analyses of peripheral blood and bone marrow.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Expert Perspectives on HSCT: Planning for Success

Figure 5 Number of AHSCT procedures for

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Outline of the AHSCT procedure

Figure 1 CAR-T-cell design

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Haploidentical BMT with Post Transplant Cyclophosphamide

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 1 HLA-haploidentical donors

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factor–Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic.

R. Handgretinger, X. Chen, M. Pfeiffer, M. Schumm, I. Mueller, T

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Summary of overall survival by Kaplan–Meier

Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide by Franco Aversa, Esther.

Figure 2 Median monthly launch price of a new anticancer drug,

Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders Orly R. Klein, Allen.

High-Dose Iodine-131-Metaiodobenzylguanidine with Haploidentical Stem Cell Transplantation and Posttransplant Immunotherapy in Children with Relapsed/Refractory.

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

Homeostatic γδ T Cell Contents Are Preserved by Granulocyte Colony-Stimulating Factor Priming and Correlate with the Early Recovery of γδ T Cell Subsets.

Figure 1 Potential strategy for belatacept-based

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Ephraim J. Fuchs, Xiao-jun Huang, Jeffrey S. Miller

Motivations, Experiences, and Perspectives of Bone Marrow and Peripheral Blood Stem Cell Donors: Thematic Synthesis of Qualitative Studies Maria C. Garcia,

HCMV Infection of Humanized Mice after Transplantation of G-CSF–Mobilized Peripheral Blood Stem Cells from HCMV-Seropositive Donors Morgan Hakki, Devorah.

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation Filippo Milano, Margaret A. Au,

Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations During Conditioning for Hematopoietic Stem Cell Transplantation Walter J.F.M.

Effect of Ex Vivo Culture of CD34+ Bone Marrow Cells on Immune Reconstitution of XSCID Dogs Following Allogeneic Bone Marrow Transplantation Douglas.

Factors Associated with Peripheral Blood Stem Cell Yield in Volunteer Donors Mobilized with Granulocyte Colony-Stimulating Factors: The Impact of Donor.

Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+

Joseph Pidala, Stephanie J

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Figure 1 Mechanisms of action of immunotherapy modalities

Eva Guinan, Leo Luzmik, Rupert Handgretinger, Ann Woolfrey

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation

A Modified Haploidentical Nonmyeloablative Transplantation without T Cell Depletion for High-Risk Acute Leukemia: Successful Engraftment and Mild GVHD

Cytomegalovirus (CMV) Infection and Disease Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation (HCT) Platforms Using a Standardized.

Figure 3 Determination of the primary site

A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant.

Bridge to transplant following Bv+Bs regimen.

Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,

Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus,

Leukemic blasts express a “hypoxia signature

Mary Eapen Biology of Blood and Marrow Transplantation

Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization Elie Richa, Mona.

How I treat acquired aplastic anemia

Figure 1 Gene-expression quantification methods

Presentation transcript:

Figure 2 Components of each transplantation platform Figure 2 | Components of each transplantation platform. Interventions on the donor or recipient that are required for each transplantation platform are shown at each stage of the transplantation procedure. Abbreviations: ATG, antithymocyte globulin; BM, bone-marrow; BMT, blood or bone-marrow transplantation; GCSF, granulocyte colony-stimulating factor; G-PBSCs, granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells; MMF, mycophenolate mofetil; PBSCs, peripheral-blood stem cells; PTCy, post-transplantation cyclophosphamide; TCD, T-cell depletion; TCR, T-cell receptor. Kanakry, C. G. et al. (2015) Modern approaches to HLA-haploidentical blood or marrow transplantation Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.128